Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis

Cutaneous Leishmaniasis Clinical Trial

— GT  

Official title:

Therapeutic Gain of Adding the Immunomodulator Pentoxifylline to the Treatment of Cutaneous Leishmaniasis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01464242
• Other study ID #: 222951928964
• Status: Completed
• Phase: Phase 2/Phase 3
• First received: October 24, 2011
• Last updated: August 22, 2016
• Start date: November 2011
• Est. completion date: December 2015

Study information

• Verified date: August 2016
• Source: Centro Internacional de Entrenamiento e Investigaciones Médicas
• Contact: n/a
• Is FDA regulated: No
• Health authority: Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether adding pentoxifylline to treatment of American cutaneous leishmaniasis with meglumine antimoniate increases the rate and speed of clinical response without diminishing safety, and to identify immune correlates of the healing response.

Description:

Failure of first line therapies for cutaneous leishmaniasis is a public health issue. Since pathogenesis of dermal leishmaniasis is mediated by the immune and inflammatory responses, resolution of disease and control of infection are intimately linked to the host response. Several investigations have substantiated "proof of principal" for the therapeutic gain of co-adjuvant immunotherapy. This study will evaluate the efficacy and safety of using pentoxifylline (PTX) as a co-adjuvant in the treatment of cutaneous leishmaniasis with meglumine antimoniate in a randomized, double-blind, controlled trial. One arm will receive meglumine antimoniate and PTX and the other arm will receive meglumine antimoniate plus placebo. Efficacy will be assessed at the end of the treatment, and 5, 7, 13 and 26 weeks after initiation of treatment. Efficacy will be measured as the proportion of patients with definitive cure at 26 weeks after initiation of treatment, and time to healing. Safety will be assessed at the end of treatment with respect to the frequency and severity of adverse events.

Blood samples will be taken to evaluate the effects of PTX invitro and ex vivo on cells of the immune system. Proliferation and secretion of cytokines relevant to the immune and inflammatory responses by peripheral blood mononuclear cells will be measured before and after treatment. Likewise, macrophages will be differentiated from peripheral blood monocytes and infected with a strain of L. panamensis transfected with the luciferase (luc) gene. The investigators will measure the capacity of patient macrophages to kill parasites before and after treatment using a luminometric assay of viable parasite burden. Additionally, the investigators will measure the expression of inducible nitric oxide synthase, an enzyme that is necessary for nitric oxide production, one of the main leishmanicidal mechanisms used by macrophages. The investigators postulate that the use of the co-adjuvant with antimonials will increase the therapeutic response and that indicators predictive of a healing response can be identified by this prospective analysis of the immune response and therapeutic outcome.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 75
• Est. completion date: December 2015
• Est. primary completion date: January 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Patients with clinical diagnosis of cutaneous leishmaniasis (parasitologic confirmation or presumptive biopsy plus a positive Montenegro skin test).

• Age between 18 and 65 years.

• Lesions of a duration equal to or greater than one month

• More than one lesion or single lesion greater than 3 cm in diameter.

• Willingness to participate in the study after being informed through a consent process approved by the institutional ethical review committee

Exclusion Criteria:

• Pregnant or lactating women, and women who are planning to conceive during the study or that reject the use of birth control methods.

• Medical conditions that compromise the immune system (HIV infection, neoplasias, diabetes mellitus, autoimmune diseases, or use of corticosteroids, immunomodulators or antineoplastic drugs).

• Medical conditions that preclude the use of antimonials or pentoxifylline (cardiac, renal, hepatic or pancreatic disease or abnormalities).

• Alcohol abuse or use of recreational drugs that interfere with adherence to treatment

• Use of drugs with antileishmanial potential during the previous 13 weeks, including pentavalent antimonials, amphotericin B, miltefosine, and pentamidine

• Use of Theophylline , anticoagulants or antiarrhythmics.

• Diffuse or disseminated leishmaniasis.

• Mucosal involvement secondary to Leishmania infection.

• Incapacity to attend the study visits or any other condition that according to the investigator could interfere with adherence to study procedures.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cutaneous Leishmaniasis
• Leishmaniasis
• Leishmaniasis, Cutaneous

Intervention

Drug:
• Meglumine antimonate
Glucantime® 20mg/kg/day IM daily for 20 days
• Placebo
Placebo 400mg orally 3 times a day for 20 days
• Pentoxifylline
Pentoxifylline 400mg orally 3 times a day for 20 days

Locations

Country	Name	City	State
Colombia	Corporación Centro Internacional de entrenamiento e Investigaciónes Médicas	Cali	Valle

Sponsors (1)

Lead Sponsor	Collaborator
Centro Internacional de Entrenamiento e Investigaciones Médicas

Country where clinical trial is conducted

Colombia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary efficacy outcome: Definitive Cure	Definitive cure, defined as complete re-epithelialization and absence of inflammatory signs in all cutaneous leishmaniasis lesions, and absence of new leishmaniasis lesions	Participants will be followed up to 26 weeks	No
Primary	Primary safety outcome: Adverse Events	Clinical and laboratory adverse events will be qualified according to the Common Toxicity Criteria for Adverse Effects (CTCAE). All unexpected non serious adverse events will be notified and expected adverse events of moderate or higher category will be reported. All serious adverse events will be reported.	Participants will be followed up to 26 weeks	Yes
Secondary	In vitro lymphoproliferation	Proliferation of peripheral blood mononuclear cells (PBMCs) after stimulation invitro with L. panamensis antigens will be measured by tritiated thymidine uptake	Participants will be followed for an average of 20 days	No
Secondary	Cytokine secretion by PBMCs	Secretion of a panel of cytokines relevant to the inflammatory and immune responses will be measured in supernatants from PBMCs cultured with L. panamensis antigens using Luminex technology	Participants will be followed for an average of 20 days	No
Secondary	Macrophage leishmanicidal capacity	Macrophages will be differentiated from peripheral blood monocytes and their leishmanicidal capacity will be measured by luminometry after infecton with luciferase-transfected promastigotes.	Participants will be followed for an average of 20 days	No
Secondary	Macrophage inducible nitric oxide synthase (iNOS) expression	Macrophage expression of iNOS after infection will be measured by quantitative real-time Polymerase Chain Reaction (RT-PCR).	Participants will be followed for an average of 20 days	No